# Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg

> **NCT06553924** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 30 (actual)

## Conditions studied

- PAH

## Interventions

- **DRUG:** Macitentan and Tadalafil film-coated tablets
- **DRUG:** PrOpsynvi® macitentan and tadalafil film-coated tablets

## Key facts

- **NCT ID:** NCT06553924
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-14
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-08-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06553924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06553924, "Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06553924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*